USD10
TRAX Shares
About First Tracks Biotherapeutics, Inc.First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
USD10
TRAX Shares
About First Tracks Biotherapeutics, Inc.First Tracks Biotherapeutics Inc is a clinical-stage biotechnology company focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. Its clinical-stage pipeline includes rosnilimab, a selective pathogenic T cell depleter, for which it completed a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA), ANB033, a CD122 antagonist, in a Phase 1b trial for celiac disease (CeD) and eosinophilic esophagitis (EoE), and ANB101, a BDCA2 modulator, in a Phase 1a trial. The company operates in one reportable segment focused on research and development activities to deliver immunology therapeutics for autoimmune and inflammatory diseases.
Stats
TRADING WINDOW
Closed
OPENS AT
Not enough data
MARKET CAP
$1.45B
OPEN PRICE
$41.06
LOW (1Y)
$14.72
HIGH (1Y)
$49.91
LOW (24H)
$40.38
HIGH (24H)
$42.00
VOLUME (24H)
$456.23K
36.38%
Price history
Time | Price | Change |
|---|---|---|
Today | $41.06 | |
1 Day | $40.46 | 0.00% |
1 Week | $41.42 | |
1 Month | $45.74 | |
1 Year | $18.60 |
Past performance is not a reliable indicator of future results.
Discover more
Popular cryptocurrencies
Popular price predictions
Legal
Information is provided for informational purposes only, and is not investment advice. This is not an invitation, inducement or recommendation to buy any particular asset, or to employ any particular investment strategy. Coinbase makes no representation as to the accuracy, suitability or validity of any information provided.All ticker names are trademarks of their respective holders. Any ticker reference does not imply affiliate with or endorsement by a third-party. Real-time prices are sourced from third parties, but not from all markets. Source: Nasdaq Last Sale. Morningstar data ©2026.